GlucoTrack, Inc., (GCTK) News

GlucoTrack, Inc., (GCTK): $2.40

0.02 (-0.83%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Filter GCTK News Items

GCTK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest GCTK News From Around the Web

Below are the latest news stories about GLUCOTRACK INC that investors may wish to consider to help them evaluate GCTK as an investment opportunity.

GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Rutherford, NJ, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today it has received a notification letter from Nasdaq Stock Market LLC (“Nasdaq”) that the Company has been granted an additional 180-day compliance period, or until May 20, 2024, to regain compliance with Nasdaq’s minimum bid price rule. In a notification letter

Yahoo | November 30, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the week with a breakdown of the biggest pre-market stock movers traders need to watch on Monday morning!

William White on InvestorPlace | November 20, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning!

William White on InvestorPlace | November 14, 2023

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter. To Our Valued Shareholders, As we near the end of 2023, we would like to express our gratitude for your continued support of the Company. We welcome this

Yahoo | November 13, 2023

GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Rutherford, NJ, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study

Yahoo | October 12, 2023

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS

Rutherford, NJ, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has appointed Erin Carter to its Board of Directors and as Chair of its Audit Committee, effective immediately. Ms. Carter brings 30 years of executive level finance experience in the medical device industry. From 2012 until March of 2023, she held va

Yahoo | August 31, 2023

GLUCOTRACK ANNOUNCES NEW VP OF MARKETING

Rutherford, NJ, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Drinda Benjamin has joined the company as Vice President of Marketing. Ms. Benjamin has over 20 years of experience in life sciences, with specific focus on commercialization of health technology. Within diabetes, she has past experiences in product deve

Yahoo | August 28, 2023

The Power Play by The Market Herald Releases New Interviews with GlucoTrack and Acceleware Discussing Their Latest News

The Power Play by The Market Herald has announced the release of new interviews with GlucoTrack and Acceleware discussing their latest news.

Yahoo | July 26, 2023

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Rutherford, NJ, July 25, 2023 (GLOBE NEWSWIRE) -- - Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device and digital health platform company focused on diabetes and prediabetes, announced today the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could

Yahoo | July 25, 2023

Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)

Aegis Capital Corp. acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ:GCTK).

Yahoo | April 17, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!